Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
OBIO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.40
vs -0.18
Q2.23
N/A
-0.35
vs -0.25
Q3.23
N/A
-0.38
vs -0.05
Q4.23
N/A
-0.37
vs -0.08
Q1.24
N/A
-0.38
vs -0.40
Q2.24
N/A
-0.45
vs -0.35
Q3.24
N/A
-0.41
vs -0.38
Q4.24
N/A
-0.37
vs -0.37
Q1.25
N/A
-0.48
vs -0.38
Q2.25
N/A
-0.49
vs -0.45
Sales Growth
YoY
Current
Estimates
Q1.23
+34%
1.2M vs 866K
Q2.23
+128%
915K vs 401K
Q3.23
-64%
419K vs 1.2M
Q4.23
-76%
262K vs 1.1M
Q1.24
-47%
620K vs 1.2M
Q2.24
-15%
778K vs 915K
Q3.24
+136%
987K vs 419K
Q4.24
-3%
253K vs 262K
Q1.25
-16%
522.3K vs 620K
Q2.25
-8%
716.7K vs 778K
Return on Equity
QoQ
Q1.23
-11%
-0.11
vs -0.01
Q2.23
-13%
-0.13
vs -0.11
Q3.23
-17%
-0.17
vs -0.13
Q4.23
-19%
-0.19
vs -0.17
Q1.24
-24%
-0.24
vs -0.19
Q2.24
-36%
-0.36
vs -0.24
Q3.24
-33%
-0.33
vs -0.36
Q4.24
-49%
-0.49
vs -0.33
Institutionnal Ownership
QoQ
Q4.22
1
1
vs NA
NA
Q1.23
22
22
vs 1
2100%
Q3.23
42
42
vs NA
NA
Q4.23
39
39
vs 42
-7%
Q1.24
42
42
vs 39
8%
Q2.24
46
46
vs 42
10%
Q3.24
47
47
vs 46
2%
Q4.24
50
50
vs 47
6%
globenewswire.com
7 hours ago
globenewswire.com
9 hours ago
globenewswire.com
16 hours ago
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.41 ( 16.67%)
Relative Strenght
9
Volume Buzz
33%
Earning Acce
Yes
Dist 52w H.
68%Forecast
1000%2025-Revenue
-358%2025-EPS
90%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
12.00(318.12%)
Number of analyst
1
Last analyst upgrade/downgrade
BTIG
initialisePrevious: Not converted
2025-03-20
Now: Buy
Barclays
initialisePrevious: Not converted
2025-01-02
Now: Overweight
H.C. Wainwright
initialisePrevious: Not converted
2024-08-22
Now: Buy
B. Riley
initialisePrevious: Not converted
2024-07-24
Now: Buy
Relative Strength
OBIO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How OBIO compares to sector?
OBIO
-2x